Inceptor Bio, a cell therapy biotechnology company, and Avectas, a cell engineering technology leader, have partnered to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.   Under the agreement, Inceptor will utilize Avectas’ SOLUPORE technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell product.  Avectas’ SOLUPORE technology is well suited to Inceptor Bio’s CAR-T...